These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9339268)

  • 21. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
    Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A
    N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline.
    Frederick Bd; Satlin A; Wald LL; Hennen J; Bodick N; Renshaw PF
    Am J Geriatr Psychiatry; 2002; 10(1):81-8. PubMed ID: 11790638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
    Mirza NR; Peters D; Sparks RG
    CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Behavioral outcomes in clinical trials for Alzheimer disease.
    Ferris SH; Mackell JA
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S10-5. PubMed ID: 9339267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
    Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel derivative of xanomeline improves fear cognition in aged mice.
    Si W; Zhang X; Niu Y; Yu H; Lei X; Chen H; Cao X
    Neurosci Lett; 2010 Apr; 473(2):115-9. PubMed ID: 20178835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.
    Satlin A; Bodick N; Offen WW; Renshaw PF
    Am J Psychiatry; 1997 Oct; 154(10):1459-61. PubMed ID: 9326834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.
    McArthur RA; Gray J; Schreiber R
    Curr Opin Investig Drugs; 2010 Jul; 11(7):740-60. PubMed ID: 20571970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type.
    Raffaele KC; Berardi A; Asthana S; Morris P; Haxby JV; Soncrant TT
    Psychopharmacol Bull; 1991; 27(3):315-9. PubMed ID: 1775605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease.
    Sramek JJ; Hurley DJ; Wardle TS; Satterwhite JH; Hourani J; Dies F; Cutler NR
    J Clin Pharmacol; 1995 Aug; 35(8):800-6. PubMed ID: 8522637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's disease.
    Sramek JJ; Cutler NR; Hurley DJ; Seifert RD
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jan; 19(1):85-91. PubMed ID: 7535938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
    Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
    Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment.
    Dunbar GC; Kuchibhatla RV; Lee G;
    J Psychopharmacol; 2011 Aug; 25(8):1020-9. PubMed ID: 20542923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. M
    Russell JK; Ingram SM; Teal LB; Lindsley CW; Jones CK
    ACS Chem Neurosci; 2023 Feb; 14(3):435-457. PubMed ID: 36655909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline.
    Wang D; Yang L; Su J; Niu Y; Lei X; Xiong J; Cao X; Hu Y; Mei B; Hu JF
    Biochem Biophys Res Commun; 2011 Jul; 410(2):229-34. PubMed ID: 21651893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavior as an efficacy outcome.
    Cummings JL
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():v-vi. PubMed ID: 9339265
    [No Abstract]   [Full Text] [Related]  

  • 38. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group.
    Thal LJ; Forrest M; Loft H; Mengel H
    Neurology; 2000 Jan; 54(2):421-6. PubMed ID: 10668706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment.
    Reisberg B; Borenstein J; Salob SP; Ferris SH; Franssen E; Georgotas A
    J Clin Psychiatry; 1987 May; 48 Suppl():9-15. PubMed ID: 3553166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.